ACRES Commercial Realty Corp.

ACRES Commercial Realty Corp.

14.20
USD
-0.60
(-4.05%)
Mar 04Next Earn
ACRES Commercial Realty Corp.
NYSE:ACR/PD
(New York Stock Exchange)

Recent

price

14.20

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
USD
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
60
89
126
104
102
88
43
59
48
56
-143
51
77
92
100
92
91
Sales/Revenue/Turnover
28.5
- -
35.84
44.58
60.72
21.49
-33.61
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
4
5
6
14
3
14
-16
3
3
3
7
14
7
5
10
10
15
Depreciation Expense
19
38
64
39
61
11
-30
34
27
36
-198
34
11
22
29
21
-51
Net Income, GAAP
22.73
24.19
18.47
- -
- -
10.89
- -
12.23
- -
- -
- -
- -
3.12
0.44
0.44
- -
- -
Effective Tax Rate (%)
32.2
42.39
51.05
37.65
59.77
11.98
-71.16
56.76
57.3
63.69
137.78
66.58
13.79
24.37
29.38
23.27
-56.17
Profit Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Working Capital
1,543
1,754
1,679
1,243
1,309
1,289
740
686
704
1,498
1,308
1,818
1,911
1,720
1,406
1,591
3,318
LT Debt
348
430
613
774
952
827
703
671
554
556
334
448
441
446
450
551
1,191
Total Equity
2.18
- -
2.24
- -
- -
0.67
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
1.06
1.85
2.88
- -
- -
0.17
- -
2.41
- -
1.53
- -
1.72
0.47
1.01
1.48
- -
- -
Return on Capital (%)
6.74
9.7
12.12
4.61
5.15
-1.58
-7.15
1.38
2.36
4.61
-46.72
4.61
-1.99
0.68
2.03
0.06
-15.62
Return on Common Equity (%)

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
- -
- -
- -
LT Borrowings
1,865
1,783
3,262
LT Finance Leases
46
46
56
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
- -
- -
Market Capitalization
- -
- -
- -

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
48
41
84
Accounts Receivable, Net
30
34
37
Inventories
- -
- -
- -
Total Current Liabilities
- -
- -
- -
Payables & Accruals
10
11
11
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-1.96%
11.37%
22.45%
Free Cash Flow
-160.49%
-17.64%
-79.68%
Net Income, GAAP
-130.65%
-14.31%
-27.17%
Sales/Revenue/Turnover
-43.29%
-12.93%
-8.04%
Total Cash Common Dividend
- -
- -
-143.48%

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
25
21
25
29
100
2025
17
22
34
19
92
2026
21
21
31
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
ACRES Commercial Realty Corp. (NYSE: ACR), a real estate investment trust founded in 2005 and headquartered at 390 RXR Plaza in Uniondale, New York, originates, holds and manages commercial real estate mortgage loans and related debt investments across the United States; its portfolio encompasses whole loans, mezzanine loans, A-notes, B-notes, preferred equity, commercial mortgage-backed securities and equity stakes through direct ownership or joint ventures, with a focus on middle-market properties in multifamily, student housing, hospitality, office and industrial sectors in top U.S. markets. Externally managed by ACRES Capital, LLC, a subsidiary of ACRES Capital Corp., the company targets transitional floating-rate loans typically ranging from $10 million to $100 million and derives income from interest payments, rental yields and strategic asset sales. Recent developments include refinancing two securitizations into a non-mark-to-market financing facility with JPMorgan post-2024 year-end, enabling a two-year reinvestment period; expansion of the share repurchase program by $10 million in 2025 for common and preferred stock; redemption of CRE securitizations and closing of a $940 million managed facility backed by commercial mortgage loans; and plans to grow the loan portfolio through new originations with experienced sponsors in high-growth markets amid healthy 2024 payoffs and renewed transactional activity.

Company News

  • Fate Therapeutics Presents New FT819 Data at ACR Convergence 2026 Highlighting Meaningful Clinical Responses in Lupus Without the Use of Conditioning Chemotherapy

  • Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2026 on the Potential of MRT-8102 in Gout

  • ACR 2026: Dapirolizumab Pegol Associated with Greater Treatment Response Rates Versus Placebo in SLE Using Novel Treatment Response Measure

  • IMP761 Late-Breaking Abstract at ACR Convergence 2026 Highlights Statistically Significant & Exposure-Dependent Inhibition of T-Cell-Driven Immune Responses

  • Velinotamig, a BCMAxCD3 T Cell Engager, Achieves Complete Renal Responses and Significantly Reduces Disease Activity in Systemic Lupus Erythematosus in Data Presented at ACR Convergence 2026

  • Cabaletta Bio Presents New Rese-cel Phase 1/2 Clinical Data at ACR Convergence 2026 Featuring Immunomodulator-Free Durability and Favorable Benefit-Risk Profile Across Autoimmune Diseases

  • ACRES Commercial Realty Corp. (ACR) Q3 2026 Earnings Call Transcript

  • argenx Presents Phase 3 ALKIVIA Data at ACR Convergence 2026 Showing Rapid and Sustained Improvement with Efgartigimod in Autoimmune Myositis

  • What ACRES Commercial Realty (ACR) Said on Its Q3 Earnings Call

  • Acrivon Expands into Immunology and Inflammation with Acquisition of Phase 2-Ready Differentiated, Oral JAK1 Inhibitor ACR-525, and PKCθ Inhibitor Preclinical Program from Aqilion AB

  • Lilly to showcase new retatrutide, Taltz (ixekizumab) and Zepbound (tirzepatide) data at ACR Convergence 2026, advancing science at the intersection of rheumatologic conditions and obesity

  • ACRES Commercial (ACR) Reports Q3 Loss, Tops Revenue Estimates

  • ACRES COMMERCIAL REALTY CORP. REPORTS RESULTS FOR THIRD QUARTER 2026

  • ACRES Commercial Realty (ACR) Set to Announce Quarterly Earnings on Wednesday

  • KBRA Publishes Ratings for ACRES Commercial Realty Corp.

  • Acrivon Announces Late-Breaking Oral Plenary Presentation of Early Phase 1/2 Clinical Results in AP3-Predicted Tumors for its First-in-Class WEE1/PKMYT1 Inhibitor ACR-2316 at the 38th EORTC-NCI-AACR Symposium

  • ACRES Commercial Realty Corp. to Report Results for Third Quarter 2026

  • Acrivon Advances ACR-7280, an Optimized, AP3-Enabled, Potential First-in-Class, Oral CDK11 Inhibitor Toward IND Filing in First Half of 2027

  • CRISPR Therapeutics to Present Clinical Data on Zugocabtagene Geleucel (Zugo-cel) in Autoimmune Disease at the American College of Rheumatology (ACR) Convergence 2026

  • Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at the American College of Rheumatology (ACR) Convergence 2026